NEULANDLAB · Healthcare
The board meets on 3 Nov 2026 to approve the results. This page fills in when the numbers are filed.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹418 cr | ₹393 cr | ₹385 cr | ₹440 cr | ₹311 cr | ₹398 cr | ₹328 cr | ₹293 cr | ₹514 cr | ₹440 cr | ₹776 cr | ₹642 cr |
| YoY | — | — | — | +21% | −26% | +1% | −15% | −33% | +65% | +11% | +137% | +119% |
| EBITDA margin | 32.8% | 30.8% | 27.8% | 28.0% | 19.9% | 21.9% | 15.5% | 11.6% | 30.4% | 17.5% | 39.6% | 34.7% |
| Other income, % of PBT | 2% | 2% | 5% | 19% | 8% | 47% | 18% | 44% | 2% | 15% | 4% | 4% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 27% | 22% | 27% | 25% | 34% | 20% | 29% | 21% | 25% | 26% | 26% | 25% |
| Net profit | ₹89.0 cr | ₹81.0 cr | ₹68.0 cr | ₹98.0 cr | ₹33.0 cr | ₹102 cr | ₹28.0 cr | ₹14.0 cr | ₹97.0 cr | ₹41.0 cr | ₹213 cr | ₹148 cr |
| YoY | — | — | — | +58% | −63% | +26% | −59% | −86% | +194% | −60% | +661% | +957% |
| Core profit YoY | — | — | — | +30% | −62% | −33% | −63% | −90% | +182% | −32% | +759% | +1,800% |
| EPS | ₹69.56 | ₹63.44 | ₹52.66 | ₹76.28 | ₹25.60 | ₹79.18 | ₹21.68 | ₹10.83 | ₹75.49 | ₹31.62 | ₹165.76 | ₹115.10 |
| Flags | · | · | · | 1 | 1 | 3 | 1 | 2 | ✓ | 1 | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.